000134843 001__ 134843
000134843 005__ 20260217205451.0
000134843 0247_ $$2doi$$a10.3389/fneur.2024.1355877
000134843 0248_ $$2sideral$$a138352
000134843 037__ $$aART-2024-138352
000134843 041__ $$aeng
000134843 100__ $$aIrimia, Pablo
000134843 245__ $$aEptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review
000134843 260__ $$c2024
000134843 5060_ $$aAccess copy available to the general public$$fUnrestricted
000134843 5203_ $$aEptinezumab, a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), was recently approved in Europe for the prophylactic treatment of migraine in adults who have at least four migraine days a month. Eptinezumab is administered by intravenous infusion every 12 weeks. During recent months, a considerable amount of evidence from eptinezumab trials has been published. The aim of this review is to describe the existing evidence on the tolerability, safety and efficacy of eptinezumab in patients with migraine. Data from randomized (PROMISE-1, PROMISE-2, RELIEF and DELIVER) and open-label (PREVAIL) phase 3 clinical trials have demonstrated the favorable effect of eptinezumab in migraine symptoms from first day of treatment. These studies showed that eptinezumab results in an overall reduction in mean monthly migraine days (MMDs), increases in the ≥50% and ≥ 75% migraine responder rates (MRRs) and improvements in patient-reported outcome measures in both patients with episodic migraine (EM) and with chronic migraine (CM), including patients who failed previous preventive treatments. The RELIEF trial also showed that eptinezumab, within 2 h of administration, reduced headache pain, migraine-associated symptoms and acute medication use when administered during a migraine attack. Eptinezumab benefits manifested as early as day 1 after dosing and with the subsequent doses lasted up to at least 2 years. Treatment-emergent adverse events reported by ≥2% of patients included upper respiratory tract infection and fatigue. Current evidence demonstrates that eptinezumab has a potent, fast-acting, sustained migraine preventive effect in patients with EM and CM. Eptinezumab has also shown to be well tolerated, supporting its use in the treatment of patients with migraine and inclusion in the current migraine therapeutic options.
000134843 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000134843 590__ $$a2.8$$b2024
000134843 592__ $$a0.993$$b2024
000134843 591__ $$aCLINICAL NEUROLOGY$$b121 / 286 = 0.423$$c2024$$dQ2$$eT2
000134843 593__ $$aNeurology (clinical)$$c2024$$dQ2
000134843 591__ $$aNEUROSCIENCES$$b162 / 314 = 0.516$$c2024$$dQ3$$eT2
000134843 593__ $$aNeurology$$c2024$$dQ2
000134843 594__ $$a5.2$$b2024
000134843 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000134843 700__ $$0(orcid)0000-0001-5139-6031$$aSantos-Lasaosa, Sonia$$uUniversidad de Zaragoza
000134843 700__ $$aPozo-Rosich, Patricia
000134843 700__ $$aLeira, Rogelio
000134843 700__ $$aPascual, Julio
000134843 700__ $$aLáinez, José Miguel
000134843 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000134843 773__ $$g15 (2024), [14 pp.]$$pFront. neurol.$$tFrontiers in Neurology$$x1664-2295
000134843 8564_ $$s1693338$$uhttps://zaguan.unizar.es/record/134843/files/texto_completo.pdf$$yVersión publicada
000134843 8564_ $$s2152216$$uhttps://zaguan.unizar.es/record/134843/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000134843 909CO $$ooai:zaguan.unizar.es:134843$$particulos$$pdriver
000134843 951__ $$a2026-02-17-20:18:59
000134843 980__ $$aARTICLE